NSEAnalysts/Institutional Investor Meet/Con. Call Updates10h ago · 18 Nov 2026, 10:20 pm

Analysts/Institutional Investor Meet/Con. Call Updates

Natco Pharma Limited · NATCOPHARM

✦ AI SummaryResults

Natco Pharma Limited has released the transcript of its earnings conference call for Q2 FY27, discussing its financial highlights and Q&A session.

Analysis Scores

Earnings Impact6/10
Growth Catalyst4/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk2/10
Liquidity Impact8/10
Market Sentiment5/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Natco Pharma Limited has informed the Exchange about Transcript

Attachments (1)

📄

NATCOPHARM_18112026222026_Concall_Transcript_13112026.pdf

pdf

Download →
View document text
18th November, 2026 Corporate Relationship Department Manager – Listing M/s. BSE Ltd. M/s. National Stock Exchange of India Ltd Mumbai 400 001 Mumbai 400 051 Scrip Code: 524816 Scrip Code: NATCOPHARM Dear Sir/Madam, Sub:- Transcript of earnings conference call held on 13th November, 2026 Ref:- Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 We are enclosing herewith the copy of transcript of the Company's earnings conference call for Q2 FY26-27 held on 13th November, 2026. The transcript is also available on the website of the Company at https://www.natcopharma.co.in/investor-relations/financials- filings. This is for your information and records Thanking you Yours faithfully For NATCO Pharma Limited Ch. Venkat Ramesh Company Secretary & Compliance Officer NATCO Pharma Limited - Earnings Call – Q2FY27 November 13, 2026 - Moderator: - Ladies and gentlemen, good day and welcome to NATCO Pharma Limited's Earnings Conference Call for the 2nd Quarter FY27. We have with us on the call Mr. Rajeev Nannapaneni - Vice Chairman and CEO, Mr. Amit Parekh - Chief Financial Officer, Mr. Rajesh Chebiyam - Executive Vice President, Crop Health Sciences and Mr. Rajeev Menon, Lead Investor Relations. - Please note that all Analysts' lines will be in listen-only mode, and there will be an opportunity for you to ask questions after management's opening remarks. Should you need any assistance during the conference call, please raise your hand from the Analyst tab on the screen. While asking questions, please identify yourself and your company. Please note that this conference is being recorded. - I now hand over the call to Mr. Rajeev Menon. Thank you, and over to you, sir. - Mr. Rajeev Menon - Lead Investor Relations, NATCO Pharma Limited: - Thank you, Vandit. Good evening and welcome everyone to NATCO's Conference Call discussing our earnings result for the 2nd Quarter of FY27. I am Rajeev Menon, Lead Investor Relations at NATCO. We hope you have received the earnings presentation and press release that was sent out earlier. Let me draw your attention to the fact that on this call we may be making certain forward-looking statements which are not necessarily historical facts. And anything said on this call which reflects our outlook for the future must be reviewed in conjunction with the risk that the company faces. We undertake no obligations to update these forward-looking statements. I would like to state that the material of the call except for Analyst questions is a property of NATCO and cannot be recorded or rebroadcasted without NATCO's express written permission. We will begin with the financial highlights and then follow with an interactive Q&A session. With that, I request our CFO, Amit Parekh to discuss the financial highlights. Over to you, sir. - Mr. Amit Parekh - CFO, NATCO Pharma Limited: - Thank you, Menon. Greetings to everyone and thank you once again for joining us in today's Earnings Call. - The company recorded consolidated total revenues of ₹1,019.4 crores in Q2FY27 compared to ₹794 crores in Q1 of FY27 and ₹1,463 crores in the corresponding quarter of the previous year. The quarter-on-quarter increase was primarily driven by the strong performance of our international formulation business. The Y-o-Y decline was largely attributable to lower lenalidomide revenue during the quarter, which was partially offset by the growth in the base business which also includes our subsidiaries. EBITDA including other income for the quarter stood at ₹310 crores, with EBITDA margin of 30.4%. Consolidated profit after tax stood at ₹202.6 crores compared to ₹206.5 crores in Q1 FY27. - With regards to our associate company Adcock Ingram Holding Limited, South Africa, the revenue for the quarter stood at ₹1,344 crores and profit after tax at ₹80.5 crores. In July 2026, we acquired additional 13.25% stake in Adcock Ingram Holding Limited, taking our total holdings to 49%. This further strengthens our strategic position in South African market and enhances our participation in the performance of Adcock Ingram. NATCO's share of profit based on 49% holding as on 30th of September 2026 was ₹29.2 crores after adjustment relating to purchase price allocation. Our domestic formulation business revenue stood at ₹145 crores. We also saw strong growth in our Brazil business. Revenue from Brazil stood at ₹121 crores, representing the growth of 66%. - Thank you all. With this, we will take question and answer. Over to you. - Moderator: - Thank you, sir. We will now open the call for Q&A session. We will wait for few minutes until the queue assembles. We request Analysts to respond to 2 questions and then return to the queue for more questions. Requesting to please introduce yourself and your company before asking the question. Please raise your hand from the Analyst tab on the screen to ask the question. We will wait for couple of minutes for Analysts to raise their hands and ask the question. - The first question is from Shekhar Jain. - Mr. Shekhar Jain - Individual Investor: - Yeah, I am an individual investor. So, I had two questions. - In March, when we announced that we have first-to-file status for Pomalidomide, I was hoping for a bit of a bump. So, what happened with the Pomalidomide first-to-file status? - And the second question is, what do we plan to do with the rights issue proceeds? Any colour on that will be very helpful. - Mr. Rajeev Nannapaneni - Vice Chairman & CEO, NATCO Pharma Limited: - First question was on Pomalidomide. We did get the first-to-file, Shekhar. But it is a shared first-to-file. I don’t remember the exact number of generic competitors. I think about 5 to 6 generic competitors came in the first wave. Because there were 5 and 6 competitors, the price erosion was quite steep. So, even though we had 180 days, the earnings bump was not too substantial that could move the earnings. It is the way it is. That is the nature of business. - The second question is on the rights. So, I think we have multiple end-use requirements. I think primarily it is to reduce the debt that we have raised for Adcock. We are also keeping some money for the possible acquisition. We are looking at various acquisitions. So, that is the end-use expectation. - Moderator: - The next question is from Bhuvanesh Bhoomi. - Mr. Bhuvanesh Bhoomi - Individual Investor: - My name is Bhuvanesh. I am an individual investor. - So, I think as of now, Revlimid sales is exhausted. So, what is the next big shot drug in our pipeline? - Mr. Rajeev Nannapaneni - Vice Chairman & CEO, NATCO Pharma Limited: - Next big, I think we have a few launches that are coming up in the next few quarters. For one is definitely Carfilzomib launch is there. It is coming up in the next few quarters. And of which one strength we have first-to-file. 60 mg is shared first-to-file and then we have Trabectedin coming up, which is a smaller product. But we are one among the two first- to-file. Then we have, these are 2 major ones in the US and then we are expecting launch of Olaparib also in the next few quarters in Brazil and Canada. So, these are the major launches coming up in the coming few quarters subject to launch and legal challenge. - Mr. Bhuvanesh Bhoomi - Individual Investor: - And sir, what's the plan about spinning of our Agri-fertilizer business going forward? - Mr. Rajesh Chebiyam - Executive Vice President Crop Health Sciences, NATCO Pharma Limited: - See, as you are aware, we did a rights issue, which basically what it does also the capital structure is now changed a bit. Because of that, we have to resubmit the file to SEBI. So, it pushes out by 4 to 6 months from the original plan. So, we're looking at maybe by mid- year, calendar year next year is when we hope to get the demerger done. - Mr. Bhuvanesh Bhoomi - Individual Investor: - Yeah. Thank you, sir. - Moderator: - Thank you. The next question is from Ramakrishnan. - What are the plans regarding th [Showing first 8,000 characters — download PDF for full document]